STEMI resident survival guide: Difference between revisions
Line 97: | Line 97: | ||
{{familytree | | D01 | | | | | D02 | |D01=<div style="float: left; text-align: left; width: 20em; padding:1em;">❑ Send to cath lab for primary PCI</div>| D02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> Evaluate for <br> ❑ The time from onset of symptoms <br> ❑ The risk of complications related to STEMI <br> ❑ The risk of bleeding with fibrinolysis <br> ❑ The presence of shock or severe HF <br> ❑ The time required for transfer to a PCI-capable hospital </div>}} | {{familytree | | D01 | | | | | D02 | |D01=<div style="float: left; text-align: left; width: 20em; padding:1em;">❑ Send to cath lab for primary PCI</div>| D02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> Evaluate for <br> ❑ The time from onset of symptoms <br> ❑ The risk of complications related to STEMI <br> ❑ The risk of bleeding with fibrinolysis <br> ❑ The presence of shock or severe HF <br> ❑ The time required for transfer to a PCI-capable hospital </div>}} | ||
{{familytree | | |!| | | | |,|-|^|-|.| }} | {{familytree | | |!| | | | |,|-|^|-|.| }} | ||
{{familytree | | E01 | | | E02 | | E03 | E01=<div style="float: left; text-align: left; width: 20em; padding:1em;">''' | {{familytree | | E01 | | | E02 | | E03 | E01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Adjunctive Antithrombotic Therapy to Support Reperfusion With Primary PCI'''</div> | E02=<div style="float: left; text-align: left; width: 15em; padding:1em;">❑ Transfer for primary PCI <br> ❑ FMC to device time as soon as possible and ≤ 120 min. </div>| E03=<div style="float: left; text-align: left; width: 15em; padding:1em;"> ❑ Administer fibrinolytic agent within 30 min of arrival </div>}} | ||
{{familytree | | | | {{familytree | |,|^|-|-|.| | | | | | }} | ||
{{familytree | {{familytree | F01 | | F02 | F01=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Antiplatelet Therapy'''<br> | ||
❑ [[P2Y12]] receptor inhibitors <br> | ❑ [[P2Y12]] receptor inhibitors <br> | ||
:❑ [[Clopidogrel]] (600 mg), or<br> | :❑ [[Clopidogrel]] (600 mg), or<br> | ||
Line 112: | Line 112: | ||
:❑ [[Tirofiban]] <br> | :❑ [[Tirofiban]] <br> | ||
::❑ Loading dose 25 mcg/kg<br> | ::❑ Loading dose 25 mcg/kg<br> | ||
::❑ Maintenance dose 0.15 mcg/kg/min</div> | ::❑ Maintenance dose 0.15 mcg/kg/min</div> | F02=<div style="float: left; text-align: left; width: 22em; padding:1em;">'''Anticoagulant Therapy'''<br> | ||
❑ [[UFH]] <br> | |||
:❑ With GP IIb/IIIa receptor antagonist planned: 50- to 70-U/kg IV bolus to achieve therapeutic ACT of 200-250 s. <br> | |||
❑ [[ | :❑ With no GP IIb/IIIa receptor antagonist planned: 70- to 100-U/kg bolus to achieve therapeutic ACT of 250-300 s.<br> | ||
:❑ | ❑ [[Bivalirudin]]: 0.75-mg/kg IV bolus, then 1.75–mg/kg/h infusion with or without prior treatment with UFH. An additional bolus of 0.3 mg/kg may be given if needed.</div>}} | ||
: | |||
:❑ | |||
: | |||
{{familytree/end}} | {{familytree/end}} | ||
UFH: Unfractionated Heparin; ACT: Activated clothing time | |||
==References== | ==References== |
Revision as of 21:28, 3 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Definition
ST elevation myocardial infarction (STEMI) is a syndrome defined by symptoms of myocardial ischemia (sudden chest pain and pressure, shortness of breath) associated with persistent ECG ST elevation and subsequent release of cardiac enzymes.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. STEMI is a life-threatening condition and must be treated as such irrespective of the causes.
Common Causes
- Rupture of high-risk plaque in the coronary arteries
- Occlusive Thrombus
Management
Diagnostic Approach
Shown below is an algorithm summarizing the diagnostic approach to STEMI based on the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction[1]
Characterize the symptoms:
❑ Diaphoresis | |||||||||||||||||||||||||||
Obtain a detailed history: ❑ Age
| |||||||||||||||||||||||||||
Examine the patient: ❑ Measure the blood pressure
| |||||||||||||||||||||||||||
Rule out life threatening alternative diagnoses: ❑ Aortic dissection | |||||||||||||||||||||||||||
Order labs and tests: | |||||||||||||||||||||||||||
Order Cardiac Enzymes
| |||||||||||||||||||||||||||
❑ Symptoms + increase in Troponin + EKG ST elevation | |||||||||||||||||||||||||||
Start treatment for STEMI | |||||||||||||||||||||||||||
Therapeutic Apporach
Shown below is an algorithm depicting the therapeutic approach to STEMI based on the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.[1]
Initial Treatment ❑ Administer 300 mg aspirin[2] ❑ Administer oxygen in patients with saturation <90%[3]
| |||||||||||||||||||||||||
Is PCI available? | |||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||
❑ Send to cath lab for primary PCI | Evaluate for ❑ The time from onset of symptoms ❑ The risk of complications related to STEMI ❑ The risk of bleeding with fibrinolysis ❑ The presence of shock or severe HF ❑ The time required for transfer to a PCI-capable hospital | ||||||||||||||||||||||||
Adjunctive Antithrombotic Therapy to Support Reperfusion With Primary PCI | ❑ Transfer for primary PCI ❑ FMC to device time as soon as possible and ≤ 120 min. | ❑ Administer fibrinolytic agent within 30 min of arrival | |||||||||||||||||||||||
Antiplatelet Therapy ❑ P2Y12 receptor inhibitors
❑ IV GP IIb/IIIa inhibitors
| Anticoagulant Therapy ❑ UFH
| ||||||||||||||||||||||||
UFH: Unfractionated Heparin; ACT: Activated clothing time
References
- ↑ 1.0 1.1 O'Gara, Patrick T.; Kushner, Frederick G.; Ascheim, Deborah D.; Casey, Donald E.; Chung, Mina K.; de Lemos, James A.; Ettinger, Steven M.; Fang, James C.; Fesmire, Francis M.; Franklin, Barry A.; Granger, Christopher B.; Krumholz, Harlan M.; Linderbaum, Jane A.; Morrow, David A.; Newby, L. Kristin; Ornato, Joseph P.; Ou, Narith; Radford, Martha J.; Tamis-Holland, Jacqueline E.; Tommaso, Carl L.; Tracy, Cynthia M.; Woo, Y. Joseph; Zhao, David X. (2013). "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction". Journal of the American College of Cardiology. 61 (4): e78–e140. doi:10.1016/j.jacc.2012.11.019. ISSN 0735-1097.
- ↑ Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ; et al. (2008). "Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 670S–707S. doi:10.1378/chest.08-0691. PMID 18574276.
- ↑ Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S; et al. (2013). "Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?". Eur Heart J. 34 (22): 1630–5. doi:10.1093/eurheartj/eht110. PMID 23554440.
- ↑ Doucet S, Malekianpour M, Théroux P, Bilodeau L, Côté G, de Guise P; et al. (2000). "Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty". Circulation. 101 (9): 955–61. PMID 10704160.
- ↑ Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL; et al. (2007). "Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention". Circulation. 115 (21): 2761–88. doi:10.1161/CIRCULATIONAHA.107.183885. PMID 17502569.
- ↑ López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H; et al. (2004). "Expert consensus document on beta-adrenergic receptor blockers". Eur Heart J. 25 (15): 1341–62. doi:10.1016/j.ehj.2004.06.002. PMID 15288162.
- ↑ Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R; et al. (2004). "Intensive versus moderate lipid lowering with statins after acute coronary syndromes". N Engl J Med. 350 (15): 1495–504. doi:10.1056/NEJMoa040583. PMID 15007110. Review in: ACP J Club. 2004 Sep-Oct;141(2):33
- ↑ Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J; et al. (2006). "Comparison of fondaparinux and enoxaparin in acute coronary syndromes". N Engl J Med. 354 (14): 1464–76. doi:10.1056/NEJMoa055443. PMID 16537663. Review in: ACP J Club. 2006 Sep-Oct;145(2):30-1